Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma.
about
Role of rituximab for first-line or relapsed aggressive B-cell lymphomaRituximab as maintenance therapy for patients with follicular lymphomaRituximab treatment strategy for patients with diffuse large B-cell lymphoma after first-line therapy: a systematic review and meta-analysisMonoclonal antibodies for the treatment of cancerRituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual MeetingSunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group.Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, utilizing similar signaling pathways and occurring concurrently: circulating cancer cells constitute an ideal target for concurrent treatmRole of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.Clinical Analysis of the HBV Infection Status of 135 Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP or CHOP/CHOP-Like Chemotherapy.Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185.Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivoSurgical decompression improves recovery from neurological deficit and may provide a survival benefit in patients with diffuse large B-cell lymphoma-associated spinal cord compression: a case-series study.Monoclonal antibodies for cancer immunotherapy.Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer.Emerging biologics in the treatment of uveitis.Diversity in antibody-based approaches to non-Hodgkin lymphoma.Transplantation for non-Hodgkin lymphoma.Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials.Managing post-transplant lymphoproliferative disorders in solid-organ transplant recipients: a review of immunosuppressant regimens.Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.Survival of patients with non-Hodgkin lymphoma in Germany in the early 21st century.Long-term survival of patients diagnosed with non-Hodgkin lymphoma after a previous malignancy.Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock.The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab.Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphomaRecent cancer survival in Germany: An analysis of common and less common cancers
P2860
Q24236580-A9930170-5DC5-4A6C-B423-D49DBFAB4DD0Q24241273-C89F36C0-8401-459D-BD72-44E473626081Q27025272-BF58BA22-2557-44FC-843A-3B87ECAE324CQ27025966-4B1C8D28-71E5-49B8-A453-CAD0D1EC1290Q28390181-E353702A-47C3-4E05-814B-567A1EDA78CBQ33394774-E2932781-6EB2-4AF5-A6F6-68DA6F035303Q35236068-889782F5-7F38-4B35-9257-031985220D3CQ35566338-209EE7EA-D2E4-4D43-8539-46DB078F7787Q35626262-5643CF1C-841E-46E0-A387-4E172A080748Q35656926-7D25DC8B-BD7F-4BEB-BCB1-D4EE6403CA60Q35941074-FF09860A-76D7-4C42-AE7B-FABFDC5DF322Q36697045-2F794668-46C1-40C9-B93A-97C1F60E817DQ36964299-63A57872-F8C9-44AF-82E9-7A9213CAD106Q37181031-38380EB2-90E7-4B65-AC77-2985808B269AQ37299843-B89740A8-41CD-47AD-A8FA-9C908FDDB679Q37754665-126906D9-167F-43B8-8291-C4BA7BA5825BQ37785097-DBB8DEEA-5E3F-415F-B3AF-520E64963F7CQ37810079-CFB47BE9-73BF-4436-A060-FC3763FABE46Q37948748-1525C2EF-992C-47CB-BF3C-4BCDB972AF5DQ38032320-C4528E03-D9CE-4778-9F81-909DC51FEB19Q38738390-B50D3720-7984-42E8-8C12-5FFA8A7B8FE4Q40253260-0DAA7698-1488-4CCF-892A-A2A6B570C551Q43445151-E59935A0-237D-40DB-8CB2-8F51CDB1C843Q43704830-DB044320-3E4F-4B78-8301-1023B1437316Q44576115-7A6D8F97-7C92-4588-B744-CAD91B7E7889Q48192887-E9EB63DD-2FB9-42C3-A087-BACDA4CCBEE5Q53062630-1C28CB31-74FD-4B9D-9709-9A275208FCEDQ53270181-9B6D535A-FF8E-4B7F-8C40-120CF5DDEDC7Q56882990-47C43138-DA25-419D-AF5E-90918993B816Q57191618-7C4C2F45-0F8E-4E66-BC21-46BBB972024A
P2860
Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Rituximab in combination with ...... essive non-Hodgkin's lymphoma.
@ast
Rituximab in combination with ...... essive non-Hodgkin's lymphoma.
@en
Rituximab in combination with ...... essive non-Hodgkin's lymphoma.
@nl
type
label
Rituximab in combination with ...... essive non-Hodgkin's lymphoma.
@ast
Rituximab in combination with ...... essive non-Hodgkin's lymphoma.
@en
Rituximab in combination with ...... essive non-Hodgkin's lymphoma.
@nl
prefLabel
Rituximab in combination with ...... essive non-Hodgkin's lymphoma.
@ast
Rituximab in combination with ...... essive non-Hodgkin's lymphoma.
@en
Rituximab in combination with ...... essive non-Hodgkin's lymphoma.
@nl
P356
P1433
P1476
Rituximab in combination with ...... essive non-Hodgkin's lymphoma.
@en
P2093
Bertrand Coiffier
P356
10.1053/SONC.2002.32749
P433
P577
2002-04-01T00:00:00Z